Gilead’s remdesivir combination with Roche’s Actemra or Eli Lilly’s Olumiant posits increased efficacy, but lackluster monotherapy data so far

Remdesivir is also being combined with ViralClear Pharmaceuticals’ merimepodib, a broad-spectrum antiviral, in a Phase II study. Credit: Shutterstock.



  • Remdesivir; Actemra; Olumiant